Chugai Pharmaceutical (OTCMKTS:CHGCY) Sees Strong Trading Volume – Should You Buy?

Shares of Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY) saw unusually-strong trading volume on Thursday. 608,157 shares changed hands during trading, an increase of 133% from the average daily volume of 260,611 shares. The stock last traded at $22.6575 and had previously closed at $21.52.

Analyst Ratings Changes

A number of brokerages recently issued reports on CHGCY. UBS Group lowered Chugai Pharmaceutical from a “strong-buy” rating to a “hold” rating in a research report on Thursday, August 6th. Nomura upgraded shares of Chugai Pharmaceutical to a “hold” rating in a report on Tuesday, September 1st. One equities research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat, Chugai Pharmaceutical presently has an average rating of “Moderate Buy”.

Chugai Pharmaceutical Price Performance

The firm has a market cap of $71.03 billion, a price-to-earnings ratio of 22.48 and a beta of 0.60. The business has a 50-day moving average of $20.73 and a 200-day moving average of $24.41.

Chugai Pharmaceutical (OTCMKTS:CHGCY) last posted its quarterly earnings results on Tuesday, October 27th. The company reported $0.27 earnings per share for the quarter. The firm had revenue of $2.54 billion for the quarter, compared to analyst estimates of $2.29 billion. Chugai Pharmaceutical had a return on equity of 24.91% and a net margin of 35.63%. As a group, equities analysts anticipate that Chugai Pharmaceutical Co., Ltd. Unsponsored ADR will post 1.00 EPS for the current fiscal year.

Chugai Pharmaceutical Company Profile

Chugai Pharmaceutical is a Japan-based research-driven pharmaceutical company that discovers, develops, manufactures and markets prescription medicines. Its work focuses on areas including oncology, immunology, hematology and neuroscience, and its portfolio includes biologic and antibody-based medicines as well as other pharmaceutical products.

The company was established in Japan in 1925 and is headquartered in Tokyo. Since 2002, Chugai has been part of the Roche Group through a strategic alliance, while continuing to operate as a Japan-based pharmaceutical company.

Chugai serves patients and healthcare providers in Japan and works with Roche to develop and commercialize medicines internationally.